- Home
- EEA vs ADAP Comparison
EEA vs ADAP Comparison
Compare EEA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- ADAP
- Stock Information
- Founded
- EEA 1986
- ADAP 2008
- Country
- EEA Germany
- ADAP United Kingdom
- Employees
- EEA N/A
- ADAP N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- ADAP Health Care
- Exchange
- EEA Nasdaq
- ADAP Nasdaq
- Market Cap
- EEA 67.9M
- ADAP 75.5M
- IPO Year
- EEA N/A
- ADAP 2015
- Fundamental
- Price
- EEA $10.24
- ADAP $0.10
- Analyst Decision
- EEA
- ADAP Buy
- Analyst Count
- EEA 0
- ADAP 6
- Target Price
- EEA N/A
- ADAP $1.35
- AVG Volume (30 Days)
- EEA 9.2K
- ADAP 6.5M
- Earning Date
- EEA 01-01-0001
- ADAP 08-11-2025
- Dividend Yield
- EEA 1.92%
- ADAP N/A
- EPS Growth
- EEA N/A
- ADAP N/A
- EPS
- EEA N/A
- ADAP N/A
- Revenue
- EEA N/A
- ADAP $179,639,000.00
- Revenue This Year
- EEA N/A
- ADAP N/A
- Revenue Next Year
- EEA N/A
- ADAP $37.22
- P/E Ratio
- EEA N/A
- ADAP N/A
- Revenue Growth
- EEA N/A
- ADAP 878.53
- 52 Week Low
- EEA $7.45
- ADAP $0.10
- 52 Week High
- EEA $9.26
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- EEA 52.39
- ADAP 26.87
- Support Level
- EEA $10.09
- ADAP $0.27
- Resistance Level
- EEA $10.51
- ADAP $0.36
- Average True Range (ATR)
- EEA 0.13
- ADAP 0.02
- MACD
- EEA -0.01
- ADAP -0.01
- Stochastic Oscillator
- EEA 35.71
- ADAP 0.96
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.